Gloria Gonzalez

Gloria Gonzalez

Company: Vivet Therapeutics

Job title: Chief Scientific Officer

Seminars:

Designing an Appropriate Immunosuppressive Regimen to Minimize Impact of the Immune Response to Administered AAV Therapies 12:00 pm

This panel will be a structured conversation designed to answer key questions such as: Discuss the best methods to circumvent the activation of both innate and adaptive immune response to the protein capsid, vector genome and transgene product to ensure no SAEs to reduce risk of clinical holds Explore immunomodulating and suppressive regimens currently used…Read more

day: Day Two

Strategies to Overcome the Action of Neutralizing Antibodies Against AAV 11:30 am

Neutralizing antibodies are the first host barrier of defence against wild type AAVs. Most of the recombinant AAV capsids used for gene therapies are identical or similar to those of wild type AAVs and their transduction if blocked by preexisting neutralizing antibodies Immune complexes of rAAV bound by IgG or IgM can trigger the complement…Read more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.